Merck, known as MSD outside the United States and Canada, on Wednesday announced that new data about its cancer drug, anti-programmed death-1 therapy Keytruda, will be presented at the 17th World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Vienna, Austria, Dec. 4-7, to be held at Messe Wien Exhibition & Congress Center.
The Keytruda clinical development program includes more than 30 tumor types in more than 360 clinical trials, including over 200 trials that combine Keytruda with other cancer treatments. Merck has an extensive research program in NSCLC and is currently advancing multiple registration-enabling studies with Keytruda as monotherapy and in combination.
Dr. Roger M. Perlmutter, president, Merck Research Laboratories, said: “Based on the meaningful results already obtained in studies evaluating the use of Keytruda in certain patients with PD-L1 positive non-small cell lung cancer, we have asked whether similar benefits might be associated with Keytruda use in treating other intrathoracic malignancies, including small cell lung cancer and malignant pleural mesothelioma. We look forward to sharing our recent findings with the scientific community as we seek to help patients facing these difficult diseases.”
A select list of Keytruda data to be featured in oral presentations includes:
- Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024.
- Long-Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE-028.
- KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab.
- Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028.
- Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021
- Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC).
- Relative Impact of Disease Management Costs in the Economics of Pembrolizumab in Previously Treated PD-L1 Positive Advanced NSCLC.